Last reviewed · How we verify
NCT04871971
Glycaemic Response and Insulinaemic Response for Nutralys S85 Plus and Whey Protein
NA trial testing 10 g NUTRALYS®S85 Plus pea protein in Healthy in 30 participants. Completed in 29 August 2022.
13 July 2022
Quick facts
| Lead sponsor | Oxford Brookes University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 30 |
| Start date | 15 September 2021 |
| Primary completion | 13 July 2022 |
| Estimated completion | 29 August 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- 10 g NUTRALYS®S85 Plus pea protein
- 20 g NUTRALYS®S85 Plus pea protein
- 10 g Whey protein concentrate
- 20 g Whey protein concentrate
- 50 g Glucose
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Oxford Brookes University
Who can join
Adults 18 to 60, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A comparison of the glycaemic response and insulinaemic response to glucose, Nutralys S85 Plus pea protein and whey protein using a single-blind, randomised, repeat measure, crossover design trial.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A randomized controlled trial in healthy participants to compare the insulinogenic effects of whey protein and pea protein co-ingested with glucose.
Thondre PS, Young E, Pledger S, Kefyalew S, et al · · 2026 · PMID 41615946 · DOI 10.1371/journal.pone.0340386
Verify or expand the search:
- PubMed search for NCT04871971
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Oxford Brookes University trials
Trials by the same sponsor.
- NCT06159296 — Effect of Inhaled Hydroxy Gas on Long COVID Symptoms · NA · unknown
- NCT05888584 — Improving Access and Recruitment to Clinical Trials for Lung Cancer Patients · NA · recruiting
- NCT05780164 — Improving Access to Lung Cancer Clinical Trials · recruiting
- NCT05839860 — Salt Intake, Hydration Status and Gastrointestinal Discomfort During Fasting · NA · completed
- NCT05412654 — Potassium Supplementation to Reduce Blood Pressure · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04871971 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oxford Brookes University
- Last refreshed: 7 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04871971.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing